Product image of Linagliptin "pharmapath" (Linagliptin) supplied by GNH India

Linagliptin "pharmapath"

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptin "pharmapath" (Linagliptin)

Linagliptin, the active ingredient in Linagliptin pharmapath, is a DPP‑4 inhibitor presented as a tablet for oral use. It improves glycaemic control by enhancing insulin secretion and reducing glucagon release in adults with type 2 diabetes mellitus, and is used as part of a comprehensive diabetes management plan.

GNH India supplies Linagliptin pharmapath as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality for patients requiring oral antidiabetic therapy.

Manufacturer / TM Owner

Pharmapath Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: lowers blood glucose by enhancing insulin secretion and reducing glucagon release.
  • Combination therapy in type 2 diabetes: added to metformin, sulfonylureas or insulin to achieve target HbA1c.
  • Patients with renal impairment: provides effective glycaemic control without dose adjustment.
  • Monotherapy in type 2 diabetes: used alone when metformin is contraindicated.
  • Adjunct to lifestyle modification: supports diet and exercise in glycaemic management.
  • Improved beta‑cell function: helps preserve pancreatic beta‑cell activity over time.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of incretin hormones such as GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic beta cells and suppress glucagon release from alpha cells, leading to reduced post‑prandial glucose excursions and improved overall glycaemic control.

Side Effects

Linagliptin may cause a range of adverse reactions, which are generally classified by frequency.

Common Side Effects

  • Nasopharyngitis: mild upper respiratory tract infection symptoms.
  • Headache: transient mild to moderate head pain.
  • Dizziness: occasional sensation of light‑headedness.
  • Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe allergic reactions: anaphylaxis, angioedema, or rash.
  • Hepatic injury: elevated liver enzymes or hepatitis.
  • Bullous skin disorders: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before initiating linagliptin therapy, consider the following precautions.

  • Renal function: monitor renal parameters, although dose adjustment is not required.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Hypersensitivity: discontinue if signs of allergic reaction appear.
  • Pregnancy and lactation: safety not established; avoid unless clearly needed.
  • Concomitant hypoglycaemic agents: monitor for increased risk of low blood sugar.
  • Store at room temperature: keep in the original pack, protect from moisture and light.

Avoid Interactions

Linagliptin can interact with other medicines; review patient medication profiles.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of hypoglycaemia.
  • Strong P‑glycoprotein inhibitors (e.g., itraconazole): may raise plasma levels.

Moderate Interactions (Monitor Closely)

  • Rifampin: may reduce linagliptin exposure.
  • Diuretics: may affect glucose control.
  • ACE inhibitors: monitor renal function and potassium levels.

Frequently Asked Questions

Linagliptin pharmapath is used to improve blood sugar control in adults with type 2 diabetes mellitus. It works as part of a broader treatment plan that may include diet, exercise, and other antidiabetic medications.

Linagliptin selectively blocks the DPP‑4 enzyme, which normally degrades incretin hormones. By preserving incretins, the drug enhances glucose‑dependent insulin release and reduces glucagon secretion, helping to lower post‑meal blood glucose levels.

The specific dose of linagliptin is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin belongs to the DPP‑4 inhibitor class, which generally has a low risk of hypoglycaemia compared with sulfonylureas and provides weight‑neutral effects. Unlike some other classes, it does not require dose adjustment in renal impairment, offering a convenient option for many patients.

Linagliptin tablets should be stored at room temperature, below 25 °C, in the original packaging. Keep them away from excess moisture, heat and direct sunlight to maintain product stability.

Linagliptin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious but rare risks include pancreatitis, severe allergic reactions such as anaphylaxis, hepatic injury, and serious skin disorders like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic reaction.

Linagliptin is contraindicated in individuals with a known hypersensitivity to the drug or any of its excipients. Patients with a history of severe pancreatitis or serious allergic reactions to DPP‑4 inhibitors should avoid its use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT